NVCR News & Events

Novocure announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy.

Sees FY26 adjusted EBITDA loss of $20M to flat. The company said, "This guidance assumes full-year low-to-mid single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $15 million to $25 million, mid-70's percent gross margin, and foreign exchange rates as of December 31, 2025."

Reports Q4 revenue $174.35M, consensus $173.36M. "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology," said Frank Leonard, CEO, Novocure. "This momentum continues in 2026 with the U.S. FDA approval of Optune Pax for pancreatic cancer, an achievement we are incredibly proud of given the exceptional challenge of developing treatment for this disease. We are well-positioned to continue to drive our patient-forward mission while prioritizing our goal of achieving profitability."

Novocure jumps 11% after CMS reinstates Medicare billing privileges